Hologic Announces Financial Results for First Quarter of Fiscal 2025
February 05, 2025
– Company Reports GAAP Diluted EPS of $0.87; Non-GAAP Diluted EPS of $1.03 at High End of Guidance –
– Revenue of $1,021.8 Million Increases 0.9%; Constant Currency Growth of 1.0% In-Line with Guidance –
– Company Lowers Full-Year Guidance for GAAP EPS, Maintains Guidance for Non-GAAP EPS –
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2024 .
“Our financial results for the first quarter of 2025 were consistent with our guidance overall,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Total revenue finished in line with our guidance on a constant currency basis, and improved profitability helped us post non-GAAP earnings per share at the high end of our range.”
Recent Highlights
- Revenue of $1,021.8 million increased 0.9% for the quarter, or 1.0% in constant currency. Fiscal first quarter revenue was reduced by the recent strengthening of the U.S. dollar, which lowered reported results by approximately $9 million compared to when the Company provided guidance in early November.
- Total organic revenue excluding COVID-19 grew 0.7%, or 0.8% on a constant currency basis. Total organic revenue excluding COVID-19 also excludes revenue from the divested blood screening and SSI businesses, and the acquired Endomagnetics business.
- Diagnostics revenue of $470.6 million increased 5.1%, or 5.2% in constant currency, primarily driven by higher molecular diagnostics sales, partially offset by lower sales of COVID-19 assays.
- Excluding COVID-19 revenue, organic diagnostics sales grew 9.0%, or 9.1% on a constant currency basis.
- Molecular diagnostics revenue increased 6.7% on both a reported and constant currency basis, primarily driven by higher sales of the Company’s BV CV/TV assay, as well as Biotheranostics lab testing.
- Excluding COVID-19 revenue, molecular diagnostics revenue grew 10.9%, or 11.0% on a constant currency basis.
- Breast Health revenue of $369.1 million decreased (2.3%), or (2.1%) in constant currency, primarily driven by lower sales of mammography capital equipment.
- Organic breast health revenue, which excludes sales from the divested SSI and acquired Endomagnetics businesses, decreased (5.9%), or (5.8%) in constant currency.
- Surgical revenue of $166.3 million grew 2.5% on both a reported and constant currency basis, primarily driven by strong international sales.
- Cash flow from operations remained strong in the first quarter at $189.3 million.
- The Company repurchased 6.8 million shares for $517 million in the first quarter of fiscal 2025, which included the completion of the previously announced $250 million accelerated share repurchase (ASR) program.
- On January 2, 2025, the Company broadened its surgical portfolio by completing the acquisition of Gynesonics, a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.
Key financial results for the fiscal first quarter are shown in the table below.

Michael Watts
Corporate Vice President, Investor Relations
Michael.Watts@hologic.com
(858) 410-8514
Peter Sattler
Senior Manager, Investor Relations
Peter.Sattler@hologic.com
(858) 410-8423
Source: Hologic, Inc.
Multimedia Files: